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Abstract 
To determine the prevalence of antibodies to Feline Coronavirus (FCoV) serotypes 1 
and 2 in Switzerland and their association with different disease manifestations, a 
serological study based on immunofluorescence tests was conducted with Swiss field 
cats using Transmissible Gastroenteritis Virus (TGEV), FCoV type 1 and FCoV 
type 2 as antigens. A total of 639 serum samples collected in the context of different 
studies from naturally infected cats were tested. The current study revealed that, with 
an apparent prevalence of 83%, FCoV serotype 1 is the most prevalent serotype in 
Switzerland. FCoV type 1 viruses induced higher antibody titers than FCoV type 2, 
and were more frequently associated with clinical signs and/or FIP. The antibody 
development in 7 cats experimentally infected with FCoV type 1 revealed that, with 
progressing duration of infection, antibodies to FCoV type 1 significantly increased 
over those to FCoV type 2. There was a significant relationship between antibody 
titers against TGEV, FCoV 1, and FCoV 2 and TGEV antigen detected the highest 
proportion of seropositive cats. 
We conclude that a vaccine against FCoV should be based on FCoV type 1-related 
antigens and that for serodiagnosis of FCoV infection TGEV should be used to attain 
the highest diagnostic efficiency. When serology is used in addition to clinical signs, 
haematology, and clinical chemistry results as an aid to diagnose clinical FIP, TGEV 
shows an equal diagnostic efficiency as FCoV antigen. 
 
 
Key words: FCoV type 1 and 2, TGEV, seroprevalence, Switzerland, FIP, cats, 
diagnostic efficiency 
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Introduction 
Intensive research has been done since the first description of the disease pattern of 
feline infectious peritonitis (FIP) in 1963 (22), and yet the epidemiology and the 
pathogenesis of the fatal disease FIP which is caused by a coronavirus is still not 
fully understood. It was shown that FIP is the single most important infectious cause 
of death in young cats resulting in the loss of 10% of seropositive kittens during the 
first year of life (7). 
As for the pathogenesis, it is generally accepted today that FCoV and FIP inducing 
viruses (FIPV) represent virulence variants of the same virus rather than separate 
virus species (40). Most FCoV mutants do not cause clinical signs, although present 
at high viral loads; only sporadically mutants are pathogenic and induce FIP (29). In 
some cases FCoV infection was found to induce mild enteric symptoms (28, 40). It 
was postulated earlier that harmless FCoV were restricted to the intestinal tract and 
that FIP development would result from the capability of a virus mutant to induce 
systemic infection (34). In the meantime, it was demonstrated by RT- PCR that FCoV 
generally induces systemic infection (11, 25, 29). Moreover, FCoV and FIPV have 
remained serologically and genetically indistinguishable. 
Antigenetically, coronaviruses are divided into five groups. Together with Canine 
Coronavirus (CCoV) and Transmissible Gastroenteritis Virus (TGEV) FCoV belongs 
to Group I. Cats seem susceptible to all Group I coronaviruses (24). Some feline 
strains are thought to origin from recombinations of FCoV and other Group I viruses, 
such as CCoV (17). 
Based on in vitro neutralization tests, FCoV were further classified into two serotypes, 
which differ in their growth characteristics in cell cultures and antigenetic relationship 
to TGEV and CCoV; however, both serotypes can cause FIP (8, 33).The serological 
distinction of FCoV type 1 from type 2 is most likely associated with differences in the 
S-gene sequence as monoclonal antibodies to the S-protein readily differentiate the 
FCoV subtypes (21). Furthermore, FCoV type 1 and 2 have a different cell tropism 
which can be explained by changes in the S-protein binding to different receptors as 
demonstrated (19). Cats recovering from FCoV infection develop especially high 
titers against the S-protein. Many new strains have recently been isolated (4, 5, 16, 
18, 26, 36) and phylogenetic examination suggests a spectrum of strains ranging 
from very feline like to more canine like rather than two distinct serotypes (4, 5, 26). 
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Whichever system is applied to classify FCoV, the association between certain FCoV 
strains and their ability to induce disease could not yet be elucidated. 
Knowledge of the serotype circulating in a given population is an important 
prerequisite for development of a FCoV vaccine in that the vaccine should be closely 
related to the field viruses. The present study was initiated to determine the 
seroprevalence of FCoV type 1 and 2 in Switzerland and find potential associations 
between the serotypes and certain disease manifestations. In addition, we aimed to 
characterize the immune response during experimental infection with FCoV 1. 
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Material and Methods 
Cats and serum samples 
A total of 667 serum samples collected from naturally and experimentally infected 
cats during different studies were tested for FCoV antibodies (Table 1). 
The kinetic of antibody development was determined in samples collected from cats 
orally infected with FCoV-Rm, a serotype 1 strain (35). Blood had been taken weekly 
during the first two months and monthly thereafter up to week 42 after infection 
(Table 1, Group E).  
To evaluate the prevalence of FCoV serotype 1 and 2 antibodies, field sera collected 
in 1996/97 (10) were used. From this collection, we randomly selected 296 cats 
considered healthy by their owners and veterinarians (Table 1, Group A). To 
determine the predominant FCoV serotype present in catteries, samples were used 
that had been collected in 21 catteries with different breeds in 2001/2002 (15) 
(Table 1, Group B). From each cattery, 3 randomly selected samples were pooled 
because of small sample volumes. 
To investigate a possible relationship between the presence of antibodies to the two 
serotypes and clinical signs, samples from the above mentioned 296 healthy cats 
and 204 clinically ill cats were tested. The latter were presented to veterinarians with 
one or more clinical signs of disease including fever, cachexia, depression, 
diarrhoea, gastrointestinal tract and/or abdominal problems. The cats originated from 
all parts of Switzerland and were of different ages, breeds, husbandry managements, 
and sexes (Table 1, Group A). 
To further characterize the relationship between the presence of antibodies to one of 
the FCoV serotypes and FIP, 30 serum samples were evaluated that had been 
randomly chosen from a collection of histopathologically confirmed FIP cases 
accumulated between 1991 and 1995 (37) (Table 1, Group C). As a reference group, 
we randomly selected 28 sera collected from diseased cats without FIP; these serum 
samples had been stored at the Clinical Laboratory of the Vetsuisse Faculty, 
University of Zurich, during the same time period (Table 1, Group D). 
To determine the immunological relationship between FCoV 1 and 2 and TGEV, 
serum samples of group A were tested for the respective antibodies. 
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Table 1: Origin of samples and grouping for the questions to be answered. 
   Serum samples 
 
Questions to 
be answered  
Group A 
field sera 
1996/97 
Group B 
catteries 
Group C 
histologically 
confirmed 
FIP cases 
Group D 
non-FIP 
cases*** 
1991-1995 
Group E 
experimentally 
infected cats 
1. Determination of the 
seroprevalence of FCoV 
serotypes in Switzerland 
63 samples 
from 21 
catteries ** 
   
2. Determination of the 
association between 
FCoV types and 
disease/symptoms 
 30 sera 28 sera  
3. Determination of the 
immunological 
relationship between 
FCoV type 1 and 2 and 
TGEV 
296 healthy 
cats and 204 
cats with 
clinical signs 
found to be 
associated 
with disease 
and/or FCoV 
infection* 
     
4. Determination of  the 
kinetics of the 
development of antibody 
titres to FCoV 1 and 2 
    
28 samples 
from 7 cats**** 
* cats showing one or more of the following symptoms: fever, cachexia, depression, diarrhoea, 
gastrointestinal tract and/or abdominal problems. 
** 3 pooled sera per cattery. 
*** Healthy cats and cats with clinical signs of non infectious origin (e.g. fracture). 
**** 4 serum samples from each cat were collected on weeks 3, 12/13, 16/17, 40/42 after experimental 
infection with FCoV- Rm (35). 
 
Immunofluorenscence Assay (IFA) 
The FCoV slides and all materials (dilution and rinse buffer, control sera, mounting 
fluid) were kindly donated by VMRD, Inc. (Pullman, WA, USA). Two different types of 
slides were used: FCoV type 1 and type 2, grown on Crandell Feline Kindey Cells 
(CrFK). The positive control sera had been obtained from ascites of confirmed FIP 
cases and titrated on both FCoV 1 and FCoV 2 slides. The negative control sera had 
been collected from clinically healthy cats. 
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Serial dilutions of 1:100, 1:400, 1:1’600, 1:6’400, 1:25’600, 1:102’400, and 1:409’600 
were prepared from all samples. The first screening was done at the dilution of 
1:6’400 to avoid false positive results by cross-contamination on the slides. Endpoint 
titers were then determined by testing the positive samples at the higher dilutions 
whereas the negative samples were further tested at lower dilutions. 
The staining procedure for indirect IFA was performed according to the 
manufacturer’s protocol. Briefly, diluted sera were incubated at 37°C for 30 minutes, 
slides were then washed for 10 minutes before the conjugate (sheep anti-feline-IgG 
polyclonal antiserum conjugated to fluorescein isothiocyanate) was added for 30 
minutes at again 37°C. After each washing step, the surfaces of the slides were dried 
with absorbing paper, preventing the wells from drying out. Each well contained 30% 
of infected and 70% of uninfected cells, which served as internal negative control. 
Serum samples in which antibodies to type 1 were higher than those to type 2 were 
designated as “antibodies to type 1” and vice versa. 
Antibodies to TGEV were tested according to Osterhaus and Horzinek (31). 
 
Quality control of the FCoV and TGEV slides 
To test the 10-wells-slides for absence of potential viral contaminants originating from 
various feline pathogens handled in our laboratory, cells were removed from the 
slides using a sterile scalpel blade and suspended in 200 µl Phosphate Buffered 
Saline (PBS) 1x. Total nucleic acids (TNA) were extracted using the MagNA Pure LC 
Total Nucleic Acid Isolation Kit (Roche Diagnostics, Rotkreuz, Switzerland) and 
eluted in 100 µl elution buffer. The extracts were tested by real-time RT-PCR and 
PCR for the following pathogens: FCoV (13), feline leukaemia virus (FeLV provirus 
PCR (38)), feline immunodeficiency virus (FIV) (27), feline herpes virus 1 (FHV-1) 
(41), feline parvo virus (FPV) (29), and feline calicivirus (FCV) (14). FCV was tested 
with the following modifications: forward primer 5’-GTT GGA TGA ACT ACC CGC 
CAA TC-3’; reverse primer 5’-CAT ATG CGG CTC TGA TGG CTT GAA ACT G-3’; 
probe 5’-FAM-TCG GTG TTT GAT TTG GCC TG-6-TAMRA-3’ (C. Helps, personal 
communications). As uninfected cells present on the slides, serving as internal 
negative control, did not show any unspecific fluorescence, the slides were not tested 
for mycoplasma contamination by PCR. 
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Molecular characterization of the FCoV 1 and 2 isolates 
To further characterize the FCoV strains used for IFA, infected cells were lysed 
directly on the slides using 500 µl RLT buffer and viral RNA was extracted by means 
of the RNeasy Mini Kit (Qiagen, Hombrechtikon, Switzerland). The extracted RNA 
was checked for FCoV by real time PCR (13). A region of about 700 base pairs of the 
S-gene of FCoV was amplified using the following primer sets: primer set 1 with 
forward primer UCD1.3502f 5’-GCA CTT AAT GCT TAT GTG TCT CAA A-3’ and 
reverse primer UCD1.4165r 5’-TGA GCC ATT CAA GGT CAA CA-3’; primer set 2 
with forward primer UCD1.3500f 5’-CAG CAC TTA ATG CTT ATG TGT CTC A-3’ 
and reverse primer UCD1.4173r 5’-CAA TCC TGT TGA GCC ATT CAA G-3’; primer 
set 3 with forward primer FIPV79-1164.3549f 5’-AGC ACT TAA TGC ATT TGT GTC 
TCA-3’ and reverse primer FIPV79-1164.4230r 5’-TTT CAA TTC TAT TGA GCC ATT 
CAA G-3’; primer set 4 with forward primer KU2.3523f 5’-GCA CTT AAT GCT TAT 
GTG TCT C-3’ and reverse primer KU2.4226r 5’-CAC ACA TAC CAA GGC C-3’; 
primer set 5 with forward primer KU2.3522f 5’-AGC ACT TAA TGC TTA TGT GC-3’ 
and reverse primer KU2.4226r (sequence above). Briefly, 2.5 µl RNA were amplified 
using the SuperScript™ III One-Step RT-PCR System with Platinum® Taq Kit 
(Invitrogen life technologies, Basel, Switzerland), 0.2 µM of each primer, in a total 
volume of 25 µl. PCR cycling conditions were as follows: 30 min at 50°C (RT step), 
2 min at 94°C, 40 cycles of 15 sec at 94°C (denaturation), 30 sec at 55°C (annealing) 
and 1 min at 68°C (elongation), followed by 5 min at 68°C. 
PCR products from conventional PCR were analyzed on 2% agarose gels; amplicons 
were purified using the MinElute Gel Extraction Kit (Qiagen) and sequenced from 
both sides. Cycle sequencing was performed with approximately 20 ng of DNA and 
3.3 pmol product-specific primers using the BigDye Terminator Cycle Sequencing 
Ready Reaction Kit v1.1 (Applied Biosystems, Rotkreuz, Switzerland). Cycling 
conditions were as follows: 1 min at 96°C, then 25 cycles at 96°C for 30 sec and 
50°C for 15 sec, followed by 60°C for 4 min. Products were purified using the DyeEx 
Spin column (Qiagen), and analyzed on the ABI Prism 310 Genetic Analyzer (Applied 
Biosystems). The sequences obtained from the 5 primer sets were aligned to one 
consensus sequence by SeqScape (Version 1.1, Applied Biosystems) and then 
compared to reference sequences of the FCoV S-gene deposited in the genebank: 
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KU2 (D32044) and UCD1 (AB088222) for typical type 1 strains and FIPV79-1183 
(X80799) and FIPV79-1164 (X06177) for type 2 strains. 
 
Statistical evaluation 
Statistical analyses were performed using StatView 5.1. (SAS Institute Inc., Cary, 
NC) and Excel Microsoft. To characterize frequencies of antibodies to serotypes with 
respect to significant differences in the different groups of cats, the χ2-test was 
applied. To evaluate the height of titers in the different groups of cats, titers were 
divided into two groups (Table 2). The association between the nature of symptoms 
and the serotypes was evaluated by means of multivariate logistic regression model. 
To determine the immunological relationship between FCoV 1 and 2 and TGEV, the 
coefficient of correlation and the regression coefficient using the least square method 
were applied. To characterize the kinetic of antibody development for significant 
differences, antibody titers were analyzed by ANOVA, factorial and repeated 
measures method, and Fisher’s PLDS post hoc test for factorial ANOVA. For the 
comparison of mean titers, the Kruskal-Wallis and the Mann-Whitney-U test were 
used. Comparison of groups was performed by using the χ2-test and the post hoc 
cell contribution as well as multivariate logistic regression model. Values of p < 0.05 
were considered statistically significant. For the presentations of frequency 
distributions in Figures 3 and 4, box-plots were used with the upper and lower levels 
of the boxes representing the 75th and 25th quantiles, the line in between 
representing the median and the wiskers the 2.5th and 97.5th quantile. Outliers are 
shown as individual dots. 
 
Table 2: Assignment of titers to two categories. 
                     Titer group 
Slide type 
Low High 
TGEV 1:25 – 1:400 1:1600 
FCoV 1:100 – 1:1,600 1:6,400 – 1:409,600 
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Results 
Quality control of the FCoV and TGEV slides 
The RT-PCR and PCR testing for potentially contaminating pathogens yielded 
negative results with the exception of FCoV RT-PCR, which was highly positive 
(TaqMan Ct values of 18 and 21 for FCoV type 1 and FCoV type 2, respectively, 
suggesting presence of comparable amounts of viral RNA). 
 
Molecular characterization of the FCoV 1 and 2 isolates 
Partial sequencing of the S-gene of FCoV isolated from FIP1 and FIP2 slides 
(GenBank Accession Numbers DQ122858 and DQ122859 respectively) revealed a 
high homology with prototypes of FCoV type 1 and 2 strains, respectively (Table 3). 
 
Table 3: Homology of FCoV antigens on IFA slides with FCoV reference strains. 
FCoV type 1 strains  FCoV type 2 strains                        Reference Sequence 
FCoV slide UCD 1 KU2  79-1183 79-1164 
FCoV slide FIP 1 91.9% 91.8%  62.6% 61.8% 
FCoV slide FIP 2 61.8% 62.3%  94.4% 95.3% 
 
Development of antibody titers to FCoV type 1 and 2 during experimental infection 
The course of infection was followed in seven cats, experimentally infected with a 
FCoV type 1 strain, over a period of 40/42 weeks (Figure 1). Antibody titers to type 1 
but not type 2 increase significantly after week 17 of the experiment. Of note, the cats 
survived the experiment and showed no clinical signs; the rise of FCoV 1 antibody 
titers did not reflect FIP development. 
 
Prevalence of FCoV serotypes in Switzerland 
Among 296 clinically healthy cats (Group A), 50% were FCoV seropositive. In 35.1% 
of the tested animals, titers to FCoV 1 were higher than those to FCoV 2, while in 
4.4% of the cats it was vice versa, and 10.5% showed identical titers for both FCoV 
types (Figure 2). 
There was no statistically significant association between the husbandry conditions 
(multicat vs. single cat household) and the prevalence of FCoV serotypes (χ2-test, 
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p = 0.07). High titers (≥ 1:1,600) to FCoV were more frequently found in cats from 
multicat than in single cat households although the difference was not significant 
(χ2-test, p = 0.06). Antibodies to FCoV type 2 had a tendency to be less frequent in 
multicat households (χ2-test, p = 0.07). 
In 15 (71%) of the 21 Swiss catteries (Group B) antibodies to type 1 were 
predominant, while in 6 (29%) catteries antibodies to type 1 and 2 were equal in 
height. In none of the catteries antibodies to type 2 were predominant (Figure 2).  
In all cats analyzed, antibody titers against FCoV type 1 were significantly higher than 
against FCoV type 2 (Figure 3). 
 
Association between the FCoV serotype and the clinical manifestation 
Among the 500 field sera from 1996/97 (Group A), seropositivity to FCoV (type 1 or 
type 2) was significantly higher in cats with clinical signs than in healthy cats (χ2-test, 
p = 0.01). In this association, antibodies to type 1 were of predominant importance for 
clinical signs. However, no statistically significant association was found between the 
presence of antibodies to type 1 and any of the six categories of clinical signs 
previously found to be associated with possible FCoV infection (multivariate logistic 
regression model, p > 0.05). 
All of the 30 samples from histopathologically confirmed FIP cases (Group C) were 
seropositive. In 25 cats (83%), type 1 titers were higher than those to type 2; the 
remaining 5 animals (17%) had identical titers to both serotypes. In none of the cats, 
titers to type 2 were higher than to type 1 (Figure 2). In the reference group of non-
FIP cases (Group D), 43% were seronegative, 50% tested higher for type 1 than for 
type 2, 7% showed identical titers to both types, and in no cat titers were higher to 
type 2 than to type 1 (Figure 2). The distribution of titers to the FCoV 1 and 2 
serotypes did not differ significantly between groups A and D (χ2-test, p > 0.2). 
Compared to non-FIP cases, the FIP cases had a significantly higher seroprevalence 
of FCoV antibodies than any other group (χ2-test, p < 0.001). In addition, the 
prevalence of antibodies to FCoV 1 was significantly higher in the FIP group than 
their reference Group D (χ2-test, p < 0.0001). 
No association could be detected between the height of titer and the type of clinical 
signs (χ2-test, p > 0.2). However, mean titers to FCoV type 1 in confirmed FIP cases 
were statistically higher than to FCoV type 1 and 2 in the control group without FIP 
(χ2-test, p < 0.0001, Figure 4). 
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Figure 1. Course of mean titers of antibodies to both FCoV 1 and 2 serotypes in cats 
experimentally infected with FCoV serotype 1. A statistically relevant specification of the 
immune system to the FCoV serotype of infection can be seen 40/42 weeks after infection 
(ANOVA with repeated measures, p = 0.038). 
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Figure 2. Prevalence of FCoV serotypes in different Swiss cat groups. Numbers on bars 
indicate the percentage of samples within the according group (A–D) referring to the four categories 
on the x-axis. Categories are defined as follows: neg: antibody titers to both FCoV serotypes below 
detectable level; FCoV 1: antibody titers to FCoV 1 > antibody titers to FCoV 2; FCoV 2: antibody 
titers to FCoV 2 > antibody titers to FCoV 1; FCoV 1=FCoV 2: antibody titers to FCoV = antibody 
titers to FCoV 2. 
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Figure 3. “Box-plot” distribution of titres to FCoV type 1 and 2. In cats with antibodies to 
FCoV type 1 (1>2), the titres were significantly higher than in cats with antibodies to FCoV type 2 
(2>1) and equal titers (1=2; Kruskal-Wallis, p < 0.0001). 
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1000000 
1< 1= 1> 
FCoV antibody titer (log 10) 
Figure 4. “Box-plot” distribution of FCoV (serotype 1 and 2) and TGEV antibody titres of 
FIP (group C) and non-FIP cases (group D). FIP cases show significantly higher FCoV/ TGEV 
antibody titres than non-FIP cases (Mann-Whitney-U, p < 0.0001 for both FCoV and TGEV). The 
ratio of median titers of FIP and non-FIP cases was identical for both, FCoV and TGEV antigen.  
TGEV FCoV 
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100 
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10000 
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1000000 
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Immunological relationship between FCoV type 1 and 2 and TEGV and diagnostic 
efficiency 
The positive correlation of titers between FCoV 1 and 2 (r = 0.76, p < 0.0001), FCoV 
type 1 and TGEV (r = 0.46, p < 0.0001), and FCoV type 2 and TGEV (r = 0.44, 
p < 0.0001) confirmed the close immunological relationship of the three antigens 
tested. 
The number of positive IFA results with FCoV 1 was similar to that obtained with 
FCoV 2 but lower than using TGEV (Figure 5). There were 88 samples that tested 
positive for TGEV but negative for FCoV; of these samples, 72% had a titer of 25, 
27% had a titer of 100, and 1% of 400. When serology in addition to the evaluation of 
clinical parameters, haematology, and clinical chemistry results was used as an aid 
to diagnose clinical FIP, TGEV antigen yielded a diagnostic efficiency identical to that 
of both FCoV serotypes (Figure 4). 
 
 
 
Figure 5. Immunological relationship between FCoV type 1 and 2 and TEGV displayed as 
intersections. Of a total of 500 serum samples, 140 tested negative for coronavirus while the 
remaining 360 samples within the circles depicted with broken lines tested positive on at least one 
of the three types of immunofluorescence slides. 210 samples tested positive on all three types of 
test slides while 88 samples were detected positive on TGEV slides and 3 on FCoV 1 only. 
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Discussion 
We have analyzed 667 serum samples from Swiss field cats and experimentally 
infected cats for FCoV antibodies using FCoV type 1 and type 2 and TGEV slides. 
We found a prevalence of FCoV 1 antibodies of 68% over FCoV 2 antibodies of 9% 
while 23% of the cats had equally high titers to type 1 and 2. 
Using molecular assays, we demonstrated that the antigen preparations were free of 
contaminating agents including FeLV, FIV, FHV-1, FPV, and FCV. Based on 
sequencing analyses of part of the FCoV S-gene, a clear assignment of the two 
viruses to prototype FCoV 1 and 2 was possible confirming the validity of the slides 
for serodiagnosis of antibodies to FCoV 1 and 2. 
 
Differentiation of antibodies to type 1 over type 2 occurs late in experimental FCoV 1 
infection 
When the antibody development to FCoV 1 and 2 was followed in experimentally 
FCoV 1 infected cats, it became clear that only after an observation period of more 
than 17 weeks antibodies to FCoV 1 showed a significant increase over those to 
FCoV 2. It suggests that during early phase of the infection crossreacting epitopes of 
both types are responsible for comparable titers. From this experiment we conclude 
that the B-lymphocytes involved undergo constant stimulation resulting in increasing 
concentrations of antibodies and affinity maturation (30) leading to ever higher 
antibody specificity to the infecting agent, i.e. to FCoV 1 over FCoV 2. Hence, a 
serological differentiation between antibodies to FCoV 1 and 2 may not be possible in 
the early phase of infection but only after the infection has resulted in an increase of 
antibody concentration and specificity. 
 
Prevalence increase of FCoV serotypes in Switzerland 
The prevalence of antibodies to FCoV in the healthy field cats was found to vary 
between 14.6% in Japan (20) to > 70% in Austria (36). We now report a FCoV 
seroprevalence of 50% in healthy Swiss cats; this is more than twofold higher than 
what we had found in a study in 1987 (28). Explanations for this increase include 
differences in sample selection and/or serologic tests. While in the earlier study 
TGEV slides were used, we now compared TGEV with FCoV type 1 and 2 slides; all 
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three antigens gave comparable results. Therefore, the prevalence increase cannot 
be attributed to the antigens used. In both studies, the criteria for sample submission 
were identical, i.e. the veterinarians submitted samples from which they had a 
personal interest in obtaining the results. The two studies were similar with respect to 
the origin of the samples (single vs. multicat households). Thus, the observed 
increase may indeed reflect an increase in seroprevalence between 1987 and 1997. 
We found predominantly FCoV type 1 antibodies (68%); this is in agreement with 
other serological surveys although the distribution varies to some degree (1, 20, 33, 
36, 39). In parallel to our experimental study, we hypothesize that serum samples 
with antibody titres to FCoV type 1 > type 2 originate from cats that had been FCoV 
type 1 infected for more than 17 weeks. Field cats with titres to FCoV type 1 equal to 
type 2 (23%) may represent cats infected with both serotypes or by either virus for a 
short period. Cats with titres to FCoV type 2 > type 1 (9%) were considered to be 
infected by a type 2 virus assuming that the antibody development after infection with 
a type 2 FCoV mirrors that of a type 1 infection with specific antibodies to FCoV 
type 2 increasing over those to type 1 with time. Overall, it becomes clear that the 
true prevalence of type 1 and 2 infection cannot be determined precisely as the 
status of the 23% of cats displaying identical titers to type 1 and 2 remains 
unresolved. 
In an earlier report (16), it was stated that cats infected with FCoV are not readily 
superinfected by antigenically related coronaviruses. However, this observation could 
not be confirmed by PCR studies conducted by others (3, 12, 20). Among the cats 
with identical titers to both serotypes the majority (59%) had high titers (≥ 1,600). This 
may reflect coinfection by both serotypes. Alternatively, it could be explained by an 
infection caused by a strain not identical but immunologically equally related to both 
strains used in the current study. Additionally, equal titers to both FCoV types could 
also be explained by antibodies against other structural proteins present in both 
viruses such as the M and N proteins.  
Based on the assumption that the virus serotypes within a cattery cluster around one 
strain (2, 16, 26), we tested pooled serum samples of randomly selected Swiss 
catteries for their predominant serotype. In none of the catteries antibody titers to 
type 2 were predominant. Along with the low seroprevalence of type 2 in individual 
cats, these data support the hypothesis that the type typically known as type 2 does 
not occur very frequently in the field. In spite of this, type 2 viruses are most 
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frequently used in laboratories. This may not reflect their importance in the field but 
rather their ease of cultivation in vitro. 
It has been reported that the type 2 FCoV originate from recombination between 
coronaviruses of cats and dogs (17). An association between presence of dogs and 
serotype 2 FCoV could not be confirmed due to the retrospective nature of the study 
in which no information on the presence of dogs had been recorded. It could be 
imagined that some of the type 2 viruses have suboptimal replication activities in vivo 
which may explain lower viral loads resulting from infection with these viruses. This 
may explain the significantly lower antibody titers in cats infected with FCoV type 2 
compared with those infected with type 1. 
The understanding of the mechanisms of the development of FIP from a FCoV 
infection is of urgent practical importance to cat owners in terms of husbandry 
measures. An association between multicat environment and height of antibody titers 
and the prevalence of FCoV infection was found in our study confirming other reports 
(9, 28). 
 
Association between the FCoV serotype and the clinical manifestation 
Antibodies against type 1 are overrepresented in diseased cats. Additionally, there is 
a tendency for type 2 to be less often present, however not at a statistically significant 
level. Similarly, in Japan, 80.4% and 10.1% of chronically diseased cats tested 
positive for FCoV type 1 and type 2, respectively (20). Thus, FCoV type 1 viruses 
may be more likely to replicate to high viral load, induce higher antibody titers, and 
thereby may become more frequently associated with chronic disease and/or FIP. 
Again, this can be explained by the better adaptation of type 1 to cats. In our study 
100% of confirmed FIP cases were seropositive to FCoV. This high seroprevalence 
in FIP cases was significantly higher compared to the healthy cat population and 
corresponds well with 87% and 96% found in other studies (6, 32). All of our FIP 
samples tested positive for type 1 or both types similarly. We could not find a single 
FIP case testing higher for type 2. Thus, the above mentioned hypothesis of FCoV 
type 1 being of higher pathogenicity than type 2 appears to be true also for FIP 
development. 
Although confirmed FIP cases showed significantly increased antibody titers to 
FCoV, no significant association could be found with height of titers and the category 
of clinical signs. 
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Immunological relationship between FCoV type 1 and 2 and TEGV and implication 
for serotesting 
The statistically significant correlation of antibody titers to FCoV 1 / FCoV 2, 
FCoV 1 / TGEV, and FCoV 2 / TGEV suggest close immunological relationship. From 
Figure 5 it becomes evident that TGEV as IFA substrate allowed detection of 88 cats 
to be seropositive which would not have been detected using FCoV 1 or FCoV 2 
antigens. The low titers of these samples (73% with titres of 25 and 27% with titres of 
100) suggest that TGEV may be a better substrate, i.e. produces higher 
concentrations of viral antigens in its pig cell line than FCoV 1 and 2 grown in cat 
cells. Alternatively, the antibodies present in these 88 samples could have been 
induced by a third type of FCoV currently not known which is more closely related to 
TGEV than FCoV. For the diagnosis of clinical FIP (37), TGEV is equally suited as 
FCoV. Therefore, for FIP diagnosis, either FCoV or TGEV can be used. It is 
emphasized, however, that coronavirus titres alone must not be used as single 
parameter for FIP diagnosis (23). However, if seropositivity is to be detected, TGEV 
in pig cells appears to be better suited. 
 
In conclusion, it was demonstrated that FCoV type 1 is the most prevalent FCoV 
serotype in Switzerland and with this the distribution is quite similar to that in other 
parts of the world. This information may be important for the development of future 
FCoV vaccines. Differentiation of the antibody response to FCoV 1 and 2 does not 
seem to be very helpful to obtain information of the disease process in a given cat. 
However, the antigens used in this study proved to be highly valuable for the 
differentiation of antibodies with specificity for FCoV 1 and 2. 
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